CStone Starts US Trial of ROR1 Conjugate Drug for Lymphoma and Solid Tumors
publication date: Mar 31, 2022
Suzhou CStone Pharma has enrolled the first patient in a US Phase I trial of CS5001, an antibody-drug conjugate that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in advanced B cell lymphomas and solid tumors. ROR1 is an oncofetal protein with low or no expression in adult tissues. However, it has high expression in leukemia and non-Hodgkin lymphoma, breast, lung, and ovarian cancers, making it an ideal ADC target. In 2020, CStone acquired global rights (ex-Korea) to CS5001 from LegoChem Biosciences in a $363 million deal. More details....
Stock Symbols: (HK: 2616) (KOSDAQ; 141080)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.